Evaluating the effect of different regimens of furosemide on edema in patients with nephrotic syndrome

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900022533

Enrollment

Unknown

Registered

2019-04-15

Start date

2019-05-01

Completion date

Unknown

Last updated

2019-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nephrotic Syndrome

Interventions

1:Furosemide, 80mg, i.v., q.d

2:Furosemide, 40mg, i.v., b.i.d

Eligibility

Sex/Gender

All

Age

15 Years to 99 Years

Inclusion criteria

Inclusion criteria: Nephrotic syndrome in line with the diagnostic criteria of primary nephrotic syndrome

Exclusion criteria

Exclusion criteria: Diabetic nephropathy, multiple myeloma kidney damage, lupus nephritis, hepatitis B-related nephropathy, purpuric nephritis, acute glomerulonephritis and so on.

Design outcomes

Primary

Measure	Time frame
Urine volume;body weight;	—

Countries

China

Contacts

Public ContactTianbiao Zhou

the Second Affiliated Hospital of Shantou University Medical College

zhoutb@aliyun.com+86 13670402516

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026